and peripheral edem dizzines URT nasopharyngiti arthralgi and headache in participants who received OM 0 AML 0 HCTZ 5 mg . With the exceptions of peripheral edema and clopidogrel arthralgia .All AEs Mild Moderate Severe Drug-related AEs a .Serious AEs All SAEs Drug-related SAEs Deaths 0 1 Discontinuations b All AEs AEs starting in the 4 open-label treatment period Drug-related AEs starting 5 3 in the open-label treatment period AEs occurring in ! on any dosing regimen Dizziness . Headache Peripheral edema Cough Upper respiratory tract infection Nasopharyngitis Urinary tract infection Back pain Arthralgia Muscle spasms . Abbreviations: adverse event;
A amlodipine besylate; olmesartan medoxomil; HC hydrochlorothiazide. a Drug-related was deed as deite probab or possibly related to randomized study medication. b Two Rucaparib participants discontinued the study due to SAEs that were considered possibly related to study medication . Data are presented as number of study participants. participants receiving OM 0 AML 0 HCTZ 5 mg than other treatment there were no clinically mean-ingful differences in AEs between treatment groups. DISCUSSION Many patients with hypertension will require ! anti-hypertensive agents in order to achieve BP goal. Consequent using a xed-dosebination may lead to more rapid goal attainme arecoline 300-08-3 enhanced adher-ence due to regimen simpli ati and better overall BP control.
The requirement for ! antihyper-tensive agents is not unexpected due to the multifacto-rial pathogenesis of the condition. 1 In a meta-analysis of data from 2 randomized tria bining agents from different antihypertensive drug classes was shown to produce a BP reduction -fold greater than that produced by doubling the dose of a single agent. 2 A and HCTZ each target a different path-way in the control of hypertensi and theseple-mentary mechanisms of action make these agents a rational choice forbination therapy. 2 Previous clinical trials have evaluated the ef acy and safety ofbining ! of these agents and have buy OSI-420 clearly demonstrated an additive BP-lowering effect. Moreov a xed-dosebination of these agen by facilitating adheren may improve the treatment of patients with resistant hypertensi deed as BP that remains above goal despite concur-rent use of antihypertensive agents of different class including a diuretic. 2 The current open-label extension of the 2-week TRINITY study demonstrates that long-term adminis-tration of thebination of OM AML HCTZ is both effective and well tolerated.
Mean baseline reduc-tions in SeDBP and SeSBP at week 2 fiT ranged from mm respectively. As a resu baseline mean SeBP decreased from fimm Hg to fimm Hg at the conclusion of the study. These BP reductions were similar to those seen in study physiology partici-pants who received the triplebination treat-ment during the Of ial Journal of the American Society of Hypertensi Inc. The Journal of Clinical Hypertension Vol 4 No March Original Articles Long-Term Effects of Incident Diabetes Mellitus on Cardiovascular Oues in People Treated for Hypertension The ALLHAT Diabetes Extension Study.